Drug intelligence / Profile preview

jaglitin

Development stage: Unknown
Lead developer: Xuanzhu Biopharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Jaglitin (XZP-3287) is an orally active, selective dipeptidyl peptidase-4 (DPP-4) inhibitor developed by Shandong Xuanzhu Pharmaceutical (a subsidiary of Sihuan Pharmaceutical) for the treatment of type 2 diabetes mellitus. By inhibiting the DPP-4 enzyme, jaglitin prevents the degradation of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This leads to increased insulin secretion and decreased glucagon levels in a glucose-dependent manner, thereby improving glycemic control. Jaglitin received approval from the China National Medical Products Administration (NMPA) in June 2024 for the management of blood glucose in adults with type 2 diabetes.

Other names: 加格列汀

Targets

CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)

Beyond the preview

Go deeper on jaglitin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on jaglitin.

Explore the full profile